High Sensitivity Multiplexed Proteomics for Systemic Biomarker Discovery

This direction is split into other directions: multiplexed cytokine profiling, enzyme-linked immunosorbent assay. Its last version stays readable and citable here.

Version 1 of 1361 papers368 conceptsfrozen 2026-10-04

In traditional clinical diagnostics, we often look for a "smoking gun"—a single protein like glucose for diabetes or troponin for a heart attack. However, complex diseases like Alzheimer’s, sepsis, or cytokine storms do not speak in single notes; they speak in chords. To understand these conditions, researchers are moving away from measuring one protein at a time toward high-sensitivity multiplexed proteomics, a set of technologies that allow us to listen to hundreds of molecular signals simultaneously from a single drop of blood.

From Single Notes to Proteomic Signatures

The historical gold standard for protein detection is the Enzyme-Linked Immunosorbent Assay (ELISA). While precise, ELISA is limited: it typically measures one protein per sample and requires relatively large volumes of fluid. If you want to track 50 different cytokines in a patient with Dengue fever, as Anusyah Rathakrishnan and colleagues did in their longitudinal map of the "cytokine storm", a traditional approach would be prohibitively slow and resource-intensive.

Multiplexing solves this by using "barcoded" detection. In bead-based systems, such as those used by Nelson Lee to study influenza-associated encephalopathy, microscopic beads are dyed with different ratios of fluorescent colors. Each color corresponds to a specific antibody. By mixing these beads together, a single test can quantify dozens of proteins at once. This allows researchers like Xiangxin Lan to identify "downregulated signatures" of cytokines that predict hypertension in pregnancies conceived via ART—a pattern that would be invisible if looking at markers in isolation.

The Sensitivity Breakthrough: Detecting the Whisper

The second half of this revolution is sensitivity. Many of the most important signaling molecules, particularly those related to brain injury or early-stage cancer, exist in the blood at "attomolar" concentrations—equivalent to a single grain of sugar dissolved in an Olympic-sized swimming pool.

Technologies like Single Molecule Arrays (Simoa) and NULISA™ achieve this by isolating individual protein molecules. As Alexis Moscoso demonstrated in a longitudinal study of Alzheimer’s Disease, digital immunoassays can detect plasma p-tau181 at levels previously undetectable. By trapping single immunocomplexes in femtoliter-sized reaction chambers, these platforms turn an analog signal into a digital "yes/no" count, providing the resolution needed to track neurodegeneration through a simple blood draw.

More recently, R. L. Kirkpatrick and team used NULISA™ technology to map the "proteomic evolution" of CAR T-cell therapy. This method converts protein binding events into DNA signals, which can then be amplified and sequenced. This allows for the simultaneous screening of thousands of proteins, revealing that severe toxicity isn't just about high inflammation, but also a failure of tissue repair mechanisms.

Why Multiplexing Works: Capturing Biological Context

The intuition behind this research direction is that context is everything. A single elevated cytokine might mean many things, but a specific ratio of proteins provides a fingerprint of a biological state.

  1. Predictive Power: Tianhong Zhang found that complement proteins are better predictors of psychosis than general inflammatory markers.
  2. Systemic Insights: Lilian Calderón‐Garcidueñas used multiplexing to show how urban air pollution creates a systemic inflammatory profile in children, affecting both the brain and bone health.
  3. Therapeutic Monitoring: In the study of "inflammaging," Carl A. Mitchell used large-scale arrays to prove that the bone marrow microenvironment itself becomes inflammatory, driving the aging of blood stem cells.

The Future of the "Liquid Biopsy"

By combining high-throughput capacity with ultra-high sensitivity, these tools are turning blood, saliva, and even the fluid inside the eye into high-resolution data streams. Whether it is Wenyan Kang identifying salivary markers for Parkinson’s or Chen‐Yang Su using aptamer-based proteomics to predict COVID-19 outcomes, the goal is the same: to catch the earliest whispers of disease before they become a roar.

This shift from "single-marker" to "signature-based" medicine allows clinicians to move beyond diagnosis toward true prognosis—predicting not just what a patient has, but how they will respond to treatment and how their disease will evolve.

Papers in this version

Showing 60 of 361 papers.

History & citationVersion 1 · 2026-10-04

Split into other directions · Permanent link

View frozen version 1

Cite this direction

Latest version (a living page):

@misc{lacuna_high_sensitivity_multiplexed_proteomics__fb3d7a2d,
  title = {High Sensitivity Multiplexed Proteomics for Systemic Biomarker Discovery},
  author = {{Lacuna}},
  howpublished = {Lacuna research direction},
  year = {2026},
  url = {https://lacuna.tiptreesystems.com/direction/high-sensitivity-multiplexed-proteomics-for-systemic-biomarker-discovery/rdr_fb3d7a2d137c4f2c927b93327f01c67f},
  note = {Latest version of a living research direction; cite a version for a fixed text. Accessed 2026-11-19},
}

This exact version (version 1, frozen text):

@misc{lacuna_high_sensitivity_multiplexed_proteomics__fb3d7a2d_v1,
  title = {High Sensitivity Multiplexed Proteomics for Systemic Biomarker Discovery},
  author = {{Lacuna}},
  howpublished = {Lacuna research direction},
  year = {2026},
  url = {https://lacuna.tiptreesystems.com/direction/high-sensitivity-multiplexed-proteomics-for-systemic-biomarker-discovery/rdr_fb3d7a2d137c4f2c927b93327f01c67f/v/1},
  note = {Version 1, frozen 2026-10-04. Accessed 2026-11-19},
}